Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis

+0.03 (+2.31%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.31 million shs
Average Volume
1.64 million shs
Market Capitalization
$73.06 million
P/E Ratio
Dividend Yield
Price Target

Marinus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
936.5% Upside
$13.79 Price Target
Short Interest
9.10% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
-0.13mentions of Marinus Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.87) to ($0.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.14 out of 5 stars

Medical Sector

167th out of 921 stocks

Pharmaceutical Preparations Industry

65th out of 418 stocks

MRNS stock logo

About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

MRNS Stock Price History

MRNS Stock News Headlines

Oppenheimer Reaffirms Their Hold Rating on Marinus (MRNS)
Marinus Pharmaceuticals (NASDAQ:MRNS) PT Lowered to $11.00
Marinus Pharmaceuticals: Q1 Earnings Snapshot
Marinus Pharmaceuticals Inc (MRNS)
See More Headlines
Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$28.29 million
Book Value
($0.30) per share


Free Float
Market Cap
$73.06 million
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Scott N. Braunstein M.D. (Age 61)
    CEO, President & Chairman
    Comp: $1.01M
  • Dr. Alex Aimetti Ph.D.
    Chief Scientific Officer
  • Ms. Sonya Weigle
    Senior VP of Investor Relations, Human Resources & Corporate Affairs
  • Ms. Martha E. Manning Esq. (Age 69)
    J. D., Senior VP, General Counsel & Secretary
  • Molly Cameron
    Director of Corporate Communications & Investor Relations
  • Dr. Kimberly A. McCormick Pharm.D.
    Chief Regulatory & Quality Assurance Officer
  • Mr. Thomas J. Lyons
    Chief Business Officer
  • Mr. David Czekai
    Senior Vice President of Chemistry, Manufacturing & Controls
  • Dr. Mark Paternoster Ph.D.
    Senior Vice President of Development
  • Dr. Dayong Li Ph.D.
    Senior Vice President of Biometrics

MRNS Stock Analysis - Frequently Asked Questions

Should I buy or sell Marinus Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRNS shares.
View MRNS analyst ratings
or view top-rated stocks.

What is Marinus Pharmaceuticals' stock price target for 2024?

7 Wall Street analysts have issued 12-month target prices for Marinus Pharmaceuticals' shares. Their MRNS share price targets range from $3.00 to $28.00. On average, they predict the company's share price to reach $13.79 in the next year. This suggests a possible upside of 936.5% from the stock's current price.
View analysts price targets for MRNS
or view top-rated stocks among Wall Street analysts.

How have MRNS shares performed in 2024?

Marinus Pharmaceuticals' stock was trading at $10.87 at the start of the year. Since then, MRNS stock has decreased by 87.8% and is now trading at $1.33.
View the best growth stocks for 2024 here

When is Marinus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our MRNS earnings forecast

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced its quarterly earnings data on Tuesday, March, 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by $0.10. The biopharmaceutical company earned $7.19 million during the quarter, compared to analyst estimates of $7.78 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 518.13% and a negative net margin of 513.80%. During the same period last year, the company posted ($0.76) earnings per share.

What ETFs hold Marinus Pharmaceuticals' stock?

ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

When did Marinus Pharmaceuticals' stock split?

Shares of Marinus Pharmaceuticals reverse split on the morning of Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Marinus Pharmaceuticals own?
Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (7.54%), Vanguard Group Inc. (5.11%), Bain Capital Life Sciences Investors LLC (2.54%), Ikarian Capital LLC (0.00%), Hussman Strategic Advisors Inc. (0.13%) and Jacobs Levy Equity Management Inc. (0.08%). Insiders that own company stock include Christina Shafer, Martha E Manning, Scott Braunstein, Seth H Z Fischer and Steven Pfanstiel.
View institutional ownership trends

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNS) was last updated on 5/19/2024 by Staff

From Our Partners